A meta-analysis of 557 patients found GLP-1 drugs effectively combat weight regain after bariatric surgery, with liraglutide producing 6 kg more loss than placebo and semaglutide outperforming liraglutide by 4% additional body weight reduction at 12 months.
-6.0 kg more than placeboLiraglutide produced 6 kg more weight loss than placebo at 6 months in post-bariatric surgery patients, with semaglutide achieving even greater results
What the researchers found
Across 8 studies and 557 individuals, liraglutide produced significantly greater weight loss than placebo after 6 months: -6.0 kg (95% CI: -8.66 to -3.33; p<0.001). Semaglutide outperformed liraglutide at both 6 months (-2.57% body weight difference; 95% CI: -3.91 to -1.23) and 12 months (-4.15% body weight difference; 95% CI: -6.96 to -1.34; p=0.004).
Semaglutide users were significantly more likely to achieve >15% weight loss (OR 2.15; p=0.03) and >10% weight loss (OR 2.10; p=0.01) at 12 months compared to liraglutide. Liraglutide significantly reduced fat mass (-4.78 kg). However, the authors noted that bone health deterioration and muscle mass loss remain concerns requiring further evaluation.
Why it matters
Up to 20-30% of bariatric surgery patients experience significant weight regain, and until recently there were few effective medical options. This is the first meta-analysis to evaluate GLP-1 drugs specifically in post-bariatric patients, providing evidence that these peptide therapies can rescue weight loss when surgery alone falls short. The finding that semaglutide outperforms liraglutide in this population gives clinicians guidance on which GLP-1 drug to choose.
How the study worked
Systematic review and meta-analysis registered in PROSPERO (CRD42023473991). Researchers searched multiple databases for randomized controlled trials, case-control, cohort, and observational studies evaluating GLP-1 receptor agonists in post-bariatric surgery patients. From 1,759 initially screened articles, 8 studies with 557 individuals met inclusion criteria. Primary outcome was weight loss after at least 3 months of therapy. Secondary outcomes included body composition changes, total adverse events, and serious adverse events.
What this study cannot tell us
Only 8 studies with 557 total participants were available, limiting statistical power. High heterogeneity (I²=79%) was observed in the liraglutide vs placebo analysis. The studies included a mix of RCTs and observational designs, introducing potential bias. Long-term data beyond 12 months was limited. The meta-analysis could not fully assess safety outcomes including bone density changes and sarcopenia risk. Different bariatric procedures (sleeve, bypass, etc.) were pooled together, though they may respond differently to GLP-1 therapy.
How to read the evidence
This is a systematic review and meta-analysis — the highest level of evidence synthesis — but is limited by the small number of included studies (8 studies, 557 patients) and high heterogeneity in some analyses. The underlying studies were a mix of RCTs and observational designs.
When this study was published
Published in 2024, this is the first meta-analysis on GLP-1 use after bariatric surgery. As more studies are published and newer GLP-1 drugs are tested in this population, the evidence base will continue to strengthen.
The bigger picture
GLP-1 receptor agonists are increasingly being recognized not just as standalone obesity treatments but as rescue therapies for patients who have already undergone bariatric surgery. This meta-analysis establishes the evidence base for what many bariatric surgeons have been doing anecdotally: prescribing GLP-1 drugs to patients with weight regain. As newer, more potent GLP-1-based drugs (like tirzepatide and retatrutide) enter the market, their role in post-surgical weight management will likely grow — but the concern about bone and muscle health must be addressed.
Questions still open
- Does GLP-1 drug use after bariatric surgery accelerate bone density loss or muscle wasting beyond what surgery alone causes?
- Would newer agents like tirzepatide produce even greater weight loss in post-bariatric patients than semaglutide?
- Should GLP-1 drugs be started proactively after bariatric surgery to prevent weight regain, rather than waiting for it to occur?
Common questions
Why do people regain weight after bariatric surgery?
Is semaglutide better than liraglutide for post-bariatric weight loss?
Read the original research
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.
Obesity surgery, 34(5), 1653-1664
Citation
Dutta, Deep; Nagendra, Lakshmi; Joshi, Ameya; Krishnasamy, Suryashri; Sharma, Meha; Parajuli, Naresh. (2024). Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.. Obesity surgery, 34(5), 1653-1664. https://doi.org/10.1007/s11695-024-07175-8